Marin Xavier, MD
Medical Oncology · San Diego, CANPI 1437211372
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $659,253 of the $918,725 with a category attached, or 71.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 13.9%. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,681 payments — averaging $546.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$128K
- AbbVie$111K
- Incyte Corporation$100K
- Lilly USA, LLC$97K
- Bristol Myers Squibb$87K
- Beigene USA, Inc.$79K
- plus $317K from 54 others
Across 89 payments — averaging $11,513 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$462K
- Incyte Corporation$267K
- AbbVie$209K
- Genentech, Inc.$62K
- E.r. Squibb & Sons, L.L.C.$15K
- Beigene, Ltd.$6K
- plus $4K from 1 others
What the payments were for
- Consulting fees$175,90319%
- Speaking & faculty fees$659,25372%
- Travel & lodging$48,8975%
- Food & beverage$34,4784%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$918,725 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 91 | $1,670,758 |
| OjjaaraMomelotinib Dihydrochloride | 47 | $1,297,067 |
| AyvakitAvapritinib | 22 | $1,152,974 |
| BrukinsaZanubrutinib | 52 | $640,905 |
| LynparzaOlaparib | 47 | $562,238 |
| VenclextaVenetoclax | 48 | $516,188 |
| CalquenceAcalabrutinib Maleate | 32 | $479,543 |
| TibsovoIvosidenib | 15 | $439,824 |
| PomalystPomalidomide | 17 | $370,431 |
| RevlimidLenalidomide | 13 | $258,250 |
| LenvimaLenvatinib Mesylate | 11 | $249,732 |
| Lenalidomide | 13 | $149,310 |
| RetacritEpoetin Alfa-Epbx | 11 | $18,292 |
| XareltoRivaroxaban | 17 | $10,845 |
| EliquisApixaban | 14 | $10,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $99,661 | $1,670,75891 claims |
| GSKOjjaara | $12,367 | $1,297,06747 claims |
| Blueprint Medicines CorporationAyvakit | $9,369 | $1,152,97422 claims |
| AstraZenecaLynparza, Calquence | $127,784 | $1,041,78179 claims |
| Beigene USA, Inc.Brukinsa | $78,795 | $640,90552 claims |
| AbbVieVenclexta | $110,664 | $516,18848 claims |
| Servier Pharmaceuticals LLCTibsovo | $112 | $439,82415 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $55,847 | $370,43117 claims |
| Bristol Myers SquibbRevlimid | $87,035 | $258,25013 claims |
| Eisai Inc.Lenvima | $464 | $249,73211 claims |
| PfizerRetacrit, Eliquis, Paxlovid | $639 | $28,72438 claims |
| Johnson & JohnsonXarelto | $4,338 | $10,84517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 379 medical oncology providers in California.
Other medical oncology in San Diego
- April TeitelbaumSan Diego$1.1M
- Klaus WagnerSan Diego$119K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.